Euroopan unioni -
suomi -
EMA (European Medicines Agency)
rybrevant
janssen-cilag international n.v. - amivantamab - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
avitcid 0.05 % emulsiovoide
orion corporation - tretinoin - emulsiovoide - 0.05 % - tretinoiini
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
avitcid 0.025 % emulsiovoide
orion corporation - tretinoin - emulsiovoide - 0.025 % - tretinoiini